Molecular signatures of immunity and immunogenicity in infection and vaccination

Frontiers in Immunology

Volumn 8, Issue NOV, 2017, Pages

  Haks, Mariëlle C ^a   Bottazzi, Barbara ^b   Cecchinato, Valentina ^c   De Gregorio, Corinne ^c   Del Giudice, Giuseppe ^d   Kaufmann, Stefan H E ^e   Lanzavecchia, Antonio ^c   Lewis, David J M ^f   Maertzdorf, Jeroen ^e   Mantovani, Alberto ^b,g   Sallusto, Federica ^c,h   Sironi, Marina ^b   Uguccioni, Mariagrazia ^c,g   Ottenhoff, Tom H M ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^c INSTITUTE FOR RESEARCH IN BIOMEDICINE   (Switzerland)

^d GSK   (Italy)

^e MAX PLANCK INSTITUTE FOR INFECTION BIOLOGY   (Germany)

^f UNIVERSITY OF SURREY   (United Kingdom)

^g HUMANITAS UNIVERSITY   (Italy)

^h ETH ZURICH   (Switzerland)

Author keywords

Assays; Biomarkers; Immunity; Immunity and infections; Vaccines

Indexed keywords

BCG VACCINE; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CD4 ANTIGEN; CHEMOKINE RECEPTOR CCR6; CHEMOKINE RECEPTOR CXCR3; GAMMA INTERFERON INDUCIBLE PROTEIN 10; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; INTERLEUKIN 18; INTERLEUKIN 18 RECEPTOR BETA; INTERLEUKIN 6; MACROPHAGE INFLAMMATORY PROTEIN 3ALPHA; NEUTRALIZING ANTIBODY; PENTRAXIN 3; PROTEIN BCL 2; RECOMBINANT BCG VACCINE; STROMAL CELL DERIVED FACTOR 1; TRANSCRIPTION FACTOR GATA 3; TRANSCRIPTION FACTOR PAX3; TRANSCRIPTOME; UNCLASSIFIED DRUG; VACCINE; VIRUS VACCINE; VPM 1002;

ADAPTIVE IMMUNITY; B LYMPHOCYTE; CD4+ T LYMPHOCYTE; CELL MIGRATION; DEUTERIUM HYDROGEN EXCHANGE; DISEASE COURSE; GENE EXPRESSION; HUMAN; IMMUNITY; IMMUNOCOMPETENT CELL; IMMUNOGENICITY; IMMUNOLOGICAL MEMORY; INFECTION; INNATE IMMUNITY; MASS SPECTROMETRY; MULTIPLEX LIGATION DEPENDENT PROBE AMPLIFICATION; MYCOBACTERIUM BOVIS BCG; OMICS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PREDICTIVE VALUE; PROGNOSTIC ASSESSMENT; PROTEOMICS; REVIEW; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; T LYMPHOCYTE; TFH CELL; TRANSCRIPTOMICS; TREATMENT RESPONSE; TUBERCULOSIS; UPREGULATION; VACCINATION; X RAY CRYSTALLOGRAPHY;

EID: 85034084455     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2017.01563     Document Type: Review

References (77)

1. Gaucher D, Therrien R, Kettaf N, Angermann BR, Boucher G, Filali-Mouhim A, et al. Yellow fever vaccine induces integrated multilineage and polyfunctional immune responses. J Exp Med (2008) 205:3119-31. doi:10.1084/jem.20082292
2. Trombetta CM, Montomoli E. Influenza immunology evaluation and correlates of protection: a focus on vaccines. Expert Rev Vaccines (2016) 15:967-76. doi:10.1586/14760584.2016.1164046
3. Joosten SA, Goeman JJ, Sutherland JS, Opmeer L, De Boer KG, Jacobsen M, et al. Identification of biomarkers for tuberculosis disease using a novel dual-color RT-MLPA assay. Genes Immun (2012) 13:71-82. doi:10.1038/gene.2011.64
4. Haks MC, Goeman JJ, Magis-Escurra C, Ottenhoff TH. Focused human gene expression profiling using dual-color reverse transcriptase multiplex ligation-dependent probe amplification. Vaccine (2015) 33:5282-8. doi:10.1016/j.vaccine.2015.04.054
5. Organization WH. Global Tuberculosis Report. Geneva, Switzerland: World Health Organisation (2016)
6. Mihret A, Loxton AG, Bekele Y, Kaufmann SH, Kidd M, Haks MC, et al. Combination of gene expression patterns in whole blood discriminate between tuberculosis infection states. BMC Infect Dis (2014) 14:257. doi:10.1186/1471-2334-14-257
7. Sutherland JS, Loxton AG, Haks MC, Kassa D, Ambrose L, Lee JS, et al. Differential gene expression of activating Fcgamma receptor classifies active tuberculosis regardless of human immunodeficiency virus status or ethnicity. Clin Microbiol Infect (2014) 20:O230-8. doi:10.1111/1469-0691.12383
8. Jenum S, Dhanasekaran S, Lodha R, Mukherjee A, Kumar Saini D, Singh S, et al. Approaching a diagnostic point-of-care test for pediatric tuberculosis through evaluation of immune biomarkers across the clinical disease spectrum. Sci Rep (2016) 6:18520. doi:10.1038/srep18520
9. Kassa D, Ran L, Jager W, Van Den Broek T, Jacobi R, Mekonen M, et al. Discriminative expression of whole blood genes in HIV patients with latent and active TB in Ethiopia. Tuberculosis (Edinb) (2016) 100:25-31. doi:10.1016/j.tube.2016.06.003
10. Gjoen JE, Jenum S, Sivakumaran D, Mukherjee A, Macaden R, Kabra SK, et al. Novel transcriptional signatures for sputum-independent diagnostics of tuberculosis in children. Sci Rep (2017) 7:5839. doi:10.1038/s41598-017-05057-x
11. Sutherland JS, Hill PC, Adetifa IM, De Jong BC, Donkor S, Joosten SA, et al. Identification of probable early-onset biomarkers for tuberculosis disease progression. PLoS One (2011) 6:e25230. doi:10.1371/journal.pone.0025230
12. Elliott TO, Owolabi O, Donkor S, Kampmann B, Hill PC, Ottenhoff TH, et al. Dysregulation of apoptosis is a risk factor for tuberculosis disease progression. J Infect Dis (2015) 212:1469-79. doi:10.1093/infdis/jiv238
13. Sloot R, Schim Van Der Loeff MF, Van Zwet EW, Haks MC, Keizer ST, Scholing M, et al. Biomarkers can identify pulmonary tuberculosis in HIV-infected drug users months prior to clinical diagnosis. EBioMedicine. (2015) 2:172-9. doi:10.1016/j.ebiom.2014.12.001
14. Zak DE, Penn-Nicholson A, Scriba TJ, Thompson E, Suliman S, Amon LM, et al. A blood RNA signature for tuberculosis disease risk: a prospective cohort study. Lancet (2016) 387:2312-22. doi:10.1016/S0140-6736(15)01316-1
15. Grode L, Seiler P, Baumann S, Hess J, Brinkmann V, Nasser Eddine A, et al. Increased vaccine efficacy against tuberculosis of recombinant Mycobacterium bovis bacille Calmette-Guerin mutants that secrete listeriolysin. J Clin Invest (2005) 115:2472-9. doi:10.1172/JCI24617
16. Kaufmann SH, Cotton MF, Eisele B, Gengenbacher M, Grode L, Hesseling AC, et al. The BCG replacement vaccine VPM1002: from drawing board to clinical trial. Expert Rev Vaccines (2014) 13:619-30. doi:10.1586/14760584.2014.905746
17. Desel C, Dorhoi A, Bandermann S, Grode L, Eisele B, Kaufmann SH. Recombinant BCG DeltaureC hly+ induces superior protection over parental BCG by stimulating a balanced combination of type 1 and type 17 cytokine responses. J Infect Dis (2011) 204:1573-84. doi:10.1093/infdis/jir592
18. Saiga H, Nieuwenhuizen N, Gengenbacher M, Koehler AB, Schuerer S, Moura-Alves P, et al. The recombinant BCG deltaureC:hly vaccine targets the AIM2 inflammasome to induce autophagy and inflammation. J Infect Dis (2015) 211:1831-41. doi:10.1093/infdis/jiu675
19. Loxton AG, Knaul JK, Grode L, Gutschmidt A, Meller C, Eisele B, et al. Safety and immunogenicity of the recombinant Mycobacterium bovis BCG vaccine VPM1002 in HIV-unexposed newborn infants in South Africa. Clin Vaccine Immunol (2017) 24(2):e439-416. doi:10.1128/CVI.00439-16
20. Grode L, Ganoza CA, Brohm C, Weiner J III, Eisele B, Kaufmann SH. Safety and immunogenicity of the recombinant BCG vaccine VPM1002 in a phase 1 open-label randomized clinical trial. Vaccine (2013) 31:1340-8. doi:10.1016/j.vaccine.2012.12.053
21. Malito E, Faleri A, Lo Surdo P, Veggi D, Maruggi G, Grassi E, et al. Defining a protective epitope on factor H binding protein, a key meningococcal virulence factor and vaccine antigen. Proc Natl Acad Sci U S A (2013) 110:3304-9. doi:10.1073/pnas.1222845110
22. Faleri A, Santini L, Brier S, Pansegrau W, Lo Surdo P, Scarselli M, et al. Two cross-reactive monoclonal antibodies recognize overlapping epitopes on Neisseria meningitidis factor H binding protein but have different functional properties. FASEB J (2014) 28:1644-53. doi:10.1096/fj.13-239012
23. Malito E, Biancucci M, Faleri A, Ferlenghi I, Scarselli M, Maruggi G, et al. Structure of the meningococcal vaccine antigen NadA and epitope mapping of a bactericidal antibody. Proc Natl Acad Sci U S A (2014) 111:17128-33. doi:10.1073/pnas.1419686111
24. Ciferri C, Chandramouli S, Donnarumma D, Nikitin PA, Cianfrocco MA, Gerrein R, et al. Structural and biochemical studies of HCMV gH/gL/gO and pentamer reveal mutually exclusive cell entry complexes. Proc Natl Acad Sci U S A (2015) 112:1767-72. doi:10.1073/pnas.1424818112
25. Ciferri C, Chandramouli S, Leitner A, Donnarumma D, Cianfrocco MA, Gerrein R, et al. Antigenic characterization of the HCMV gH/gL/gO and pentamer cell entry complexes reveals binding sites for potently neutralizing human antibodies. PLoS Pathog (2015) 11:e1005230. doi:10.1371/journal.ppat.1005230
26. Bertoldi I, Faleri A, Galli B, Lo Surdo P, Liguori A, Norais N, et al. Exploiting chimeric human antibodies to characterize a protective epitope of Neisseria adhesin A, one of the Bexsero vaccine components. FASEB J (2016) 30:93-101. doi:10.1096/fj.15-273813
27. Cariccio VL, Domina M, Benfatto S, Venza M, Venza I, Faleri A, et al. Phage display revisited: epitope mapping of a monoclonal antibody directed against Neisseria meningitidis adhesin A using the PROFILER technology. MAbs. (2016) 8:741-50. doi:10.1080/19420862.2016.1158371
28. Pirrone GF, Iacob RE, Engen JR. Applications of hydrogen/deuterium exchange MS from 2012 to 2014. Anal Chem (2015) 87:99-118. doi:10.1021/ac5040242
29. Baerga-Ortiz A, Hughes CA, Mandell JG, Komives EA. Epitope mapping of a monoclonal antibody against human thrombin by H/D-exchange mass spectrometry reveals selection of a diverse sequence in a highly conserved protein. Protein Sci (2002) 11:1300-8. doi:10.1110/ps.4670102
30. Goodnow CC, Vinuesa CG, Randall KL, Mackay F, Brink R. Control systems and decision making for antibody production. Nat Immunol (2010) 11:681-8. doi:10.1038/ni.1900
31. Crotty S. Follicular helper CD4 T cells (TFH). Annu Rev Immunol (2011) 29:621-63. doi:10.1146/annurev-immunol-031210-101400
32. Shulman Z, Gitlin AD, Targ S, Jankovic M, Pasqual G, Nussenzweig MC, et al. T follicular helper cell dynamics in germinal centers. Science (2013) 341:673-7. doi:10.1126/science.1241680
33. Bentebibel SE, Lopez S, Obermoser G, Schmitt N, Mueller C, Harrod C, et al. Induction of ICOS+CXCR3+CXCR5+ TH cells correlates with antibody responses to influenza vaccination. Sci Transl Med (2013) 5:176ra132. doi:10.1126/scitranslmed.3005191
34. Schmitt N, Bentebibel SE, Ueno H. Phenotype and functions of memory Tfh cells in human blood. Trends Immunol (2014) 35:436-42. doi:10.1016/j.it.2014.06.002
35. Spensieri F, Borgogni E, Zedda L, Bardelli M, Buricchi F, Volpini G, et al. Human circulating influenza-CD4+ ICOS1+IL-21+ T cells expand after vaccination, exert helper function, and predict antibody responses. Proc Natl Acad Sci U S A (2013) 110:14330-5. doi:10.1073/pnas.1311998110
36. Spensieri F, Siena E, Borgogni E, Zedda L, Cantisani R, Chiappini N, et al. Early rise of blood T follicular helper cell subsets and baseline immunity as predictors of persisting late functional antibody responses to vaccination in humans. PLoS One (2016) 11:e0157066. doi:10.1371/journal.pone.0157066
37. Sallusto F. Heterogeneity of human CD4(+) T cells against microbes. Annu Rev Immunol (2016) 34:317-34. doi:10.1146/annurev-immunol-032414-112056
38. Sallusto F, Lanzavecchia A. Heterogeneity of CD4+ memory T cells: functional modules for tailored immunity. Eur J Immunol (2009) 39:2076-82. doi:10.1002/eji.200939722
39. Becattini S, Latorre D, Mele F, Foglierini M, De Gregorio C, Cassotta A, et al. T cell immunity. Functional heterogeneity of human memory CD4(+) T cell clones primed by pathogens or vaccines. Science (2015) 347:400-6. doi:10.1126/science.1260668
40. Acosta-Rodriguez EV, Napolitani G, Lanzavecchia A, Sallusto F. Interleukins 1beta and 6 but not transforming growth factor-beta are essential for the differentiation of interleukin 17-producing human T helper cells. Nat Immunol (2007) 8:942-9. doi:10.1038/ni1496
41. Corti D, Voss J, Gamblin SJ, Codoni G, Macagno A, Jarrossay D, et al. A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins. Science (2011) 333:850-6. doi:10.1126/science.1205669
42. Pappas L, Foglierini M, Piccoli L, Kallewaard NL, Turrini F, Silacci C, et al. Rapid development of broadly influenza neutralizing antibodies through redundant mutations. Nature (2014) 516:418-22. doi:10.1038/nature13764
43. Lira SA. A passport into the lymph node. Nat Immunol (2005) 6:866-8. doi:10.1038/ni0905-866
44. Bachelerie F, Ben-Baruch A, Burkhardt AM, Combadiere C, Farber JM, Graham GJ, et al. International Union of Basic and Clinical Pharmacology. [corrected]. LXXXIX. Update on the extended family of chemokine receptors and introducing a new nomenclature for atypical chemokine receptors. Pharmacol Rev (2014) 66:1-79. doi:10.1124/pr.113.007724
45. Gouwy M, Schiraldi M, Struyf S, Van Damme J, Uguccioni M. Possible mechanisms involved in chemokine synergy fine tuning the inflammatory response. Immunol Lett (2012) 145:10-4. doi:10.1016/j.imlet.2012.04.005
46. Schiraldi M, Raucci A, Munoz LM, Livoti E, Celona B, Venereau E, et al. HMGB1 promotes recruitment of inflammatory cells to damaged tissues by forming a complex with CXCL12 and signaling via CXCR4. J Exp Med (2012) 209:551-63. doi:10.1084/jem.20111739
47. Venereau E, Schiraldi M, Uguccioni M, Bianchi ME. HMGB1 and leukocyte migration during trauma and sterile inflammation. Mol Immunol (2013) 55:76-82. doi:10.1016/j.molimm.2012.10.037
48. Cecchinato V, D'Agostino G, Raeli L, Uguccioni M. Chemokine interaction with synergy-inducing molecules: fine tuning modulation of cell trafficking. J Leukoc Biol (2016) 99:851-5. doi:10.1189/jlb.1MR1015-457R
49. Proudfoot AE, Uguccioni M. Modulation of chemokine responses: synergy and cooperativity. Front Immunol (2016) 7:183. doi:10.3389/fimmu.2016.00183
50. Cecchinato V, Bernasconi E, Speck RF, Proietti M, Sauermann U, D'Agostino G, et al. Impairment of CCR6+ and CXCR3+ Th cell migration in HIV-1 infection is rescued by modulating actin polymerization. J Immunol (2017) 198:184-95. doi:10.4049/jimmunol.1600568
51. Brenchley JM, Price DA, Schacker TW, Asher TE, Silvestri G, Rao S, et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med (2006) 12:1365-71. doi:10.1038/nm1511
52. Marchetti G, Tincati C, Silvestri G. Microbial translocation in the pathogenesis of HIV infection and AIDS. Clin Microbiol Rev (2013) 26:2-18. doi:10.1128/CMR.00050-12
53. Wang C, Kang SG, Lee J, Sun Z, Kim CH. The roles of CCR6 in migration of Th17 cells and regulation of effector T-cell balance in the gut. Mucosal Immunol (2009) 2:173-83. doi:10.1038/mi.2008.84
54. Baenziger S, Heikenwalder M, Johansen P, Schlaepfer E, Hofer U, Miller RC, et al. Triggering TLR7 in mice induces immune activation and lymphoid system disruption, resembling HIV-mediated pathology. Blood (2009) 113:377-88. doi:10.1182/blood-2008-04-151712
55. Dominguez-Villar M, Gautron AS, De Marcken M, Keller MJ, Hafler DA. TLR7 induces anergy in human CD4(+) T cells. Nat Immunol (2015) 16:118-28. doi:10.1038/ni.3036
56. Jacobson JM, Bosinger SE, Kang M, Belaunzaran-Zamudio P, Matining RM, Wilson CC, et al. The effect of chloroquine on immune activation and interferon signatures associated with HIV-1. AIDS Res Hum Retroviruses (2016) 32:636-47. doi:10.1089/AID.2015.0336
57. Arnold CR, Wolf J, Brunner S, Herndler-Brandstetter D, Grubeck-Loebenstein B. Gain and loss of T cell subsets in old age-age-related reshaping of the T cell repertoire. J Clin Immunol (2011) 31:137-46. doi:10.1007/s10875-010-9499-x
58. Singh T, Newman AB. Inflammatory markers in population studies of aging. Ageing Res Rev (2011) 10:319-29. doi:10.1016/j.arr.2010.11.002
59. Black S, De Gregorio E, Rappuoli R. Developing vaccines for an aging population. Sci Transl Med (2015) 7:281s288. doi:10.1126/scitranslmed.aaa0722
60. Mosca F, Tritto E, Muzzi A, Monaci E, Bagnoli F, Iavarone C, et al. Molecular and cellular signatures of human vaccine adjuvants. Proc Natl Acad Sci U S A (2008) 105:10501-6. doi:10.1073/pnas.0804699105
61. Garlanda C, Bottazzi B, Bastone A, Mantovani A. Pentraxins at the crossroads between innate immunity, inflammation, matrix deposition, and female fertility. Annu Rev Immunol (2005) 23:337-66. doi:10.1146/annurev.immunol.23.021704.115756
62. Bottazzi B, Inforzato A, Messa M, Barbagallo M, Magrini E, Garlanda C, et al. The pentraxins PTX3 and SAP in innate immunity, regulation of inflammation and tissue remodelling. J Hepatol (2016) 64:1416-27. doi:10.1016/j.jhep.2016.02.029
63. Jaillon S, Peri G, Delneste Y, Fremaux I, Doni A, Moalli F, et al. The humoral pattern recognition receptor PTX3 is stored in neutrophil granules and localizes in extracellular traps. J Exp Med (2007) 204:793-804. doi:10.1084/jem.20061301
64. Jeannin P, Bottazzi B, Sironi M, Doni A, Rusnati M, Presta M, et al. Complexity and complementarity of outer membrane protein A recognition by cellular and humoral innate immunity receptors. Immunity (2005) 22:551-60. doi:10.1016/j.immuni.2005.03.008
65. Moalli F, Doni A, Deban L, Zelante T, Zagarella S, Bottazzi B, et al. Role of complement and Fc(gamma) receptors in the protective activity of the long pentraxin PTX3 against Aspergillus fumigatus. Blood (2010) 116:5170-80. doi:10.1182/blood-2009-12-258376
66. Doni A, Garlanda C, Bottazzi B, Meri S, Garred P, Mantovani A. Interactions of the humoral pattern recognition molecule PTX3 with the complement system. Immunobiology (2012) 217:1122-8. doi:10.1016/j.imbio.2012.07.004
67. Bonavita E, Gentile S, Rubino M, Maina V, Papait R, Kunderfranco P, et al. PTX3 is an extrinsic oncosuppressor regulating complement-dependent inflammation in cancer. Cell (2015) 160:700-14. doi:10.1016/j.cell.2015.01.004
68. Doni A, Musso T, Morone D, Bastone A, Zambelli V, Sironi M, et al. An acidic microenvironment sets the humoral pattern recognition molecule PTX3 in a tissue repair mode. J Exp Med. (2015) 212:905-25. doi:10.1084/jem.20141268
69. Bottazzi B, Santini L, Savino S, Giuliani MM, Duenas Diez AI, Mancuso G, et al. Recognition of Neisseria meningitidis by the long pentraxin PTX3 and its role as an endogenous adjuvant. PLoS One (2015) 10:e0120807. doi:10.1371/journal.pone.0120807
70. Chorny A, Casas-Recasens S, Sintes J, Shan M, Polentarutti N, Garcia-Escudero R, et al. The soluble pattern recognition receptor PTX3 links humoral innate and adaptive immune responses by helping marginal zone B cells. J Exp Med. (2016) 213:2167-85. doi:10.1084/jem.20150282
71. Reading PC, Bozza S, Gilbertson B, Tate M, Moretti S, Job ER, et al. Antiviral activity of the long chain pentraxin PTX3 against influenza viruses. J Immunol (2008) 180:3391-8. doi:10.4049/jimmunol.180.5.3391
72. Olesen R, Wejse C, Velez DR, Bisseye C, Sodemann M, Aaby P, et al. DC-SIGN (CD209), pentraxin 3 and vitamin D receptor gene variants associate with pulmonary tuberculosis risk in West-Africans. Genes Immun (2007) 8:456-67. doi:10.1038/sj.gene.6364410
73. Chiarini M, Sabelli C, Melotti P, Garlanda C, Savoldi G, Mazza C, et al. PTX3 genetic variations affect the risk of Pseudomonas aeruginosa airway colonization in cystic fibrosis patients. Genes Immun (2010) 11:665-70. doi:10.1038/gene.2010.41
74. Cunha C, Aversa F, Lacerda JF, Busca A, Kurzai O, Grube M, et al. Genetic PTX3 deficiency and aspergillosis in stem-cell transplantation. N Eng J Med (2014) 370:421-32. doi:10.1056/NEJMoa1211161
75. Jaillon S, Moalli F, Ragnarsdottir B, Bonavita E, Puthia M, Riva F, et al. The humoral pattern recognition molecule PTX3 is a key component of innate immunity against urinary tract infection. Immunity (2014) 40:621-32. doi:10.1016/j.immuni.2014.02.015
76. Wojtowicz A, Lecompte TD, Bibert S, Manuel O, Rueger S, Berger C, et al. PTX3 polymorphisms and invasive mold infections after solid organ transplant. Clin Infect Dis. (2015) 61:619-22. doi:10.1093/cid/civ386
77. Fisher CE, Hohl TM, Fan W, Storer BE, Levine DM, Zhao LP, et al. Validation of single nucleotide polymorphisms in invasive aspergillosis following hematopoietic cell transplantation. Blood (2017) 129:2693-701. doi:10.1182/blood-2016-10-743294